News Select Year All Years 2026 (21) 2025 (37) 2024 (31) 2023 (31) 2022 (35) 2021 (28) 2020 (36) 2019 (46) 2018 (51) 2017 (34) 2016 (26) 2015 (42) 2014 (30) 2013 (26) 2012 (23) 2011 (28) 2010 (36) 2009 (39) 2008 (55) 2007 (50) Clinical Trials Select Clinical Trial AWARE-1 (21) BRACELET-1 (10) GOBLET (35) Search … July 26, 2017 Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress June 29, 2017 Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc. June 27, 2017 Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego June 1, 2017 Oncolytics Biotech® Announces Closing of Public Offering of Units May 24, 2017 Oncolytics Biotech® Prices Public Offering of Units May 23, 2017 Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017 May 23, 2017 Oncolytics Biotech® Announces Proposed Public Offering May 17, 2017 Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers May 8, 2017 Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer May 5, 2017 Oncolytics Biotech® Inc. Announces 2017 First Quarter Results Newer Page 34 of 71 Older